分子品管市场－全球产业规模、份额、趋势、机会及预测（依产品、分析物类型、应用、最终用户、地区及竞争格局划分，2021-2031年）

全球分子品管市场预计将从 2025 年的 3.4 亿美元成长到 2031 年的 5.1 亿美元，复合年增长率为 6.99%。

分子品管是一项关键基准，检验使用合成或生物材料进行的核酸检测的准确性，并确认临床诊断的可靠性。这一增长主要得益于对实验室认证标准（例如 ISO 15189）的严格遵守，这些标准要求定期进行能力验证测试；此外，传染病检查和基因检测的兴起也需要检验的控制通讯协定。

儘管有这些正面因素，但由于第三方管理高成本以及与低温运输管理相关的物流挑战，开发中地区的市场渗透仍面临重大障碍。营运数据凸显了该行业为应对日益复杂的检测而做出的调整。例如，美国病理学家协会 (CAP) 于 2024 年推出了 18 项新的能力认证项目，以满足临床检查室不断变化的需求。

市场驱动因素

分子诊断技术的进步，特别是次世代定序(NGS) 和多重检测的广泛应用，是推动先进品管解决方案需求的关键因素。随着检查室部署高通量系统来分析复杂的遗传标记，对能够检验广泛基因组检测并确保遗传疾病筛检和肿瘤学准确性的多分析物质控试剂的需求日益增长。 Illumina 公司在 2024 年 2 月发布的 2023 财年 10-K 报告中也强调了这项先进基因组基础设施的扩展，报告指出 NovaSeq X 仪器的出货量为 352 台，凸显了需要严格品质保证的高复杂度检测的激增。

同时，感染疾病的日益严峻促使人们迫切需要大规模分子检测和严格检验诊断的准确性。全球对快速病原体检测的日益重视，推动了临床工作流程向分子技术转型，而这需要持续的能力验证测试，以确保符合监管要求并保障病人安全。例如，根据世界卫生组织（世卫组织）于2023年11月发布的《2023年全球结核病报告》，分子诊断的使用将达到顶峰，届时47%的结核病初诊将采用世卫组织建议的快速分子检测方法。为了支持如此大规模的运营，Bio-Rad Laboratories报告称，其2024年临床诊断业务的净销售额约为15.3亿美元，这充分体现了其在诊断信心和检测支持方面的巨大价值。

市场挑战

第三方分子品管产品的高昂采购成本是市场成长的主要障碍，尤其是在资源匮乏的环境中。新兴经济体的临床检查室往往面临资金限制，难以证明购买昂贵的独立品管以及其他营运需求的合理性。因此，这些机构可能会降低品管措施的频率，或依赖标准较低的内部品管品，这不仅减少了商业生产商的商机，也损害了诊断结果的全球标准化。

此外，严格的低温运输物流要求也加重了这些经济负担。分子检测品管通常需要在零度以下储存以保持稳定性，而基础设施不稳定的地区往往难以满足此要求。这种物流上的脆弱性会导致产品劣化和废弃物增加，进一步阻碍了分散式设施的部署。这些营运压力的影响在近期的行业趋势中显而易见：根据诊断和实验室医学协会 (ADLM) 2024 年的一项调查，由于合规成本不断上涨和资源限制，48% 的实验室正在考虑停止某些检测服务，从而缩小了分子品管产品的潜在市场。

市场趋势

随着独立第三方品管材料的使用日益增多，市场格局正在发生重塑。为了满足严格的认证要求，临床检查室优先考虑的是客观的评估工具，而非试剂盒配件。这项转变的驱动力在于降低批间差异，并确保不同试剂批次间诊断准确性的一致性，这对于符合 ISO 15189 标准至关重要。实验室正积极采用这些独立材料，以识别可能被製造商提供的品管优化基质相容性所掩盖的系统性误差。这项需求反映在 Bio-Rad Laboratories 于 2024 年 10 月发布的「2024 财年第三季财务业绩」中，其临床诊断部门报告净销售额达 3.888 亿美元，主要得益于全球对品管产品的需求。

同时，为了简化高通量检测环境下的工作流程，业界正经历着向多重、多分析物对照品的重大转变。随着诊断试剂生产商将多种标靶整合到单一的综合征检测组合中，尤其是在消化器官系统和呼吸道病原体方面，检查室需要能够一次检验所有标靶的整合对照品，从而降低单分析物对照品相关的耗材成本和时间。这种整合增强了现代诊断中心的扩充性，Levity 于 2024 年 11 月发布的 2024 年第三季财务报告便印证了这一点。报告指出，诊断业务部门的收入达到 3.83 亿美元（年增 6%），这主要得益于专业分子和免疫诊断解决方案的持续普及。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球分子品管市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（独立控制、设备特定控制）
  • 依分析物类型（单分析物对照、多分析物对照）
  • 依应用领域（感染疾病诊断、肿瘤检测、基因检测等）
  • 按最终用户划分（诊断检查室、医院、体外诊断试剂生产商和合约研究组织、学术研究机构等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美分子品管市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲分子品管市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区分子品管市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲分子品管市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲分子品管市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球分子品管市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Anchor Molecular Inc.
• Thermo Fisher Scientific, Inc.
• Randox Laboratories Ltd.
• Abbott Laboratories Inc.
• Fortress Diagnostics Ltd
• Ortho-Clinical Diagnostics, Inc.
• Sun Diagnostics, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Molecular Quality Control Market is projected to expand from USD 0.34 Billion in 2025 to USD 0.51 Billion by 2031, registering a CAGR of 6.99%. Functioning as critical benchmarks, molecular quality controls employ synthetic or biological materials to validate nucleic acid testing precision and confirm the reliability of clinical diagnostics. This growth is primarily underpinned by strict adherence to laboratory accreditation norms, such as ISO 15189, which mandate regular proficiency testing, coupled with the increasing volume of infectious disease and genetic testing that necessitates verified control protocols.

Despite these positive indicators, market penetration in developing areas faces significant hurdles due to the high expense of third-party controls and the logistical difficulties associated with cold-chain management. Operational data highlights the industry's adaptation to increasing testing complexity; for instance, the College of American Pathologists launched 18 new proficiency testing programs in 2024 to meet the shifting requirements of clinical laboratories.

Market Driver

Advancements in molecular diagnostic technologies, specifically the widespread adoption of Next-Generation Sequencing and multiplex assays, are a major force behind the demand for sophisticated quality control solutions. As laboratories implement high-throughput systems to examine complex genetic markers, there is an intensified need for multi-analyte controls capable of validating extensive genomic panels, ensuring accuracy in hereditary disease screening and oncology. This expansion of advanced genomic infrastructure is evidenced by Illumina's 'Form 10-K Fiscal Year 2023' report from February 2024, which noted the shipment of 352 NovaSeq X instruments, highlighting the broader footprint of high-complexity testing that requires rigorous quality assurance.

Simultaneously, the increasing prevalence of infectious diseases serves as a catalyst, demanding high-volume molecular testing and strict verification of diagnostic precision. The global focus on rapid pathogen detection has reoriented clinical workflows toward molecular techniques, which require ongoing proficiency testing to ensure regulatory compliance and patient safety. For example, the World Health Organization's 'Global Tuberculosis Report 2023', released in November 2023, indicated that molecular diagnostics usage reached a peak, with 47% of initial tuberculosis diagnoses utilizing a WHO-recommended rapid molecular test. Supporting the scale of these operations, Bio-Rad Laboratories reported in 2024 that its Clinical Diagnostics segment achieved approximately $1.53 billion in annual net sales, demonstrating the significant value placed on diagnostic assurance and testing support.

Market Challenge

The substantial cost of acquiring third-party molecular quality controls represents a major obstacle to market growth, especially in resource-limited settings. Clinical laboratories in emerging economies often face financial constraints, making it difficult to justify the purchase of premium, independent control materials amidst other operational needs. As a result, these facilities might decrease the frequency of quality control measures or resort to less stringent in-house options, which reduces revenue opportunities for commercial manufacturers and compromises the global standardization of diagnostic outcomes.

Additionally, the strict logistical demands for maintaining cold-chain integrity during storage and transport intensify these financial burdens. Molecular controls typically require preservation at sub-zero temperatures to remain stable, a requirement often difficult to meet in areas with inconsistent infrastructure. This logistical vulnerability results in product spoilage and increased waste, further discouraging adoption in decentralized locations. The consequences of such operational pressures are highlighted by recent industry trends; according to a 2024 survey by the Association for Diagnostics & Laboratory Medicine, 48% of laboratories intended to stop specific testing services due to the growing weight of compliance costs and resource limitations, thereby shrinking the potential market for molecular quality control products.

Market Trends

The market is being reshaped by the rising utilization of independent third-party quality controls, as clinical laboratories prioritize unbiased assessment tools over kit-included options to satisfy strict accreditation requirements. This transition is motivated by the necessity to reduce lot-to-lot variability and ensure consistent diagnostic accuracy across various reagent batches, which is essential for ISO 15189 compliance. Laboratories are actively adopting these independent materials to identify systematic errors that might be obscured by the optimized matrix compatibility of manufacturer-supplied controls, a demand reflected in Bio-Rad Laboratories' 'Third-Quarter 2024 Financial Results' from October 2024, where the Clinical Diagnostics segment reported $388.8 million in net sales driven largely by global demand for quality control products.

In parallel, the industry is undergoing a notable shift toward multiplexed and multi-analyte control panels aimed at enhancing workflow efficiency in high-volume testing settings. As diagnostic manufacturers combine multiple targets into single syndromic panels-especially for gastrointestinal and respiratory pathogens-laboratories need consolidated control materials capable of validating all targets at once, thereby cutting down on consumable costs and time associated with single-analyte controls. This consolidation bolsters the scalability of modern diagnostic centers, a trend supported by Revvity's 'Financial Results for the Third Quarter of 2024' in November 2024, which showed the Diagnostics segment generating $383 million in revenue, a 6% increase attributed to the continued adoption of specialized molecular and immunodiagnostic solutions.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Anchor Molecular Inc.
• Thermo Fisher Scientific, Inc.
• Randox Laboratories Ltd.
• Abbott Laboratories Inc.
• Fortress Diagnostics Ltd
• Ortho-Clinical Diagnostics, Inc.
• Sun Diagnostics, LLC

Report Scope

In this report, the Global Molecular Quality Control Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Quality Control Market, By Product

• Independent Controls
• Instrument-Specific Controls

Molecular Quality Control Market, By Analyte Type

• Single-Analyte Controls
• Multi-Analyte Controls

Molecular Quality Control Market, By Application

• Infectious Disease Diagnostics
• Oncology Testing
• Genetic Testing
• Others

Molecular Quality Control Market, By End-User

• Diagnostic Laboratories
• Hospitals
• IVD Manufacturers & Contract Research Organizations
• Academic & Research Institutes
• Others

Molecular Quality Control Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Quality Control Market.

Available Customizations:

Global Molecular Quality Control Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Quality Control Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Independent Controls, Instrument-Specific Controls)
  • 5.2.2. By Analyte Type (Single-Analyte Controls, Multi-Analyte Controls)
  • 5.2.3. By Application (Infectious Disease Diagnostics, Oncology Testing, Genetic Testing, Others)
  • 5.2.4. By End-User (Diagnostic Laboratories, Hospitals, IVD Manufacturers & Contract Research Organizations, Academic & Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Molecular Quality Control Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Analyte Type
  • 6.2.3. By Application
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Quality Control Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Analyte Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Molecular Quality Control Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Analyte Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Molecular Quality Control Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Analyte Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-User

7. Europe Molecular Quality Control Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Analyte Type
  • 7.2.3. By Application
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Molecular Quality Control Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Analyte Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Molecular Quality Control Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Analyte Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Molecular Quality Control Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Analyte Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Molecular Quality Control Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Analyte Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Molecular Quality Control Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Analyte Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-User

8. Asia Pacific Molecular Quality Control Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Analyte Type
  • 8.2.3. By Application
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Molecular Quality Control Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Analyte Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Molecular Quality Control Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Analyte Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Molecular Quality Control Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Analyte Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Molecular Quality Control Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Analyte Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Molecular Quality Control Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Analyte Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Molecular Quality Control Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Analyte Type
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Molecular Quality Control Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Analyte Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Molecular Quality Control Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Analyte Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Molecular Quality Control Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Analyte Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-User

10. South America Molecular Quality Control Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Analyte Type
  • 10.2.3. By Application
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Molecular Quality Control Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Analyte Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Molecular Quality Control Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Analyte Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Molecular Quality Control Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Analyte Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Molecular Quality Control Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Bio-Rad Laboratories, Inc.
• 15.4. Anchor Molecular Inc.
• 15.5. Thermo Fisher Scientific, Inc.
• 15.6. Randox Laboratories Ltd.
• 15.7. Abbott Laboratories Inc.
• 15.8. Fortress Diagnostics Ltd
• 15.9. Ortho-Clinical Diagnostics, Inc.
• 15.10. Sun Diagnostics, LLC

16. Strategic Recommendations

17. About Us & Disclaimer